Pharma Deals Review, Vol 2005, No 55 (2005)

Font Size:  Small  Medium  Large

MedImmune Seeks Portfolio Expansion with Medarex Collaboration

Business Review Editor

Abstract


MedImmune and Medarex entered into research & development agreement for Medarex’s MDX-1103 and MDX-1333 antibodies that are in preclinical trials for treating autoimmune diseases such as systemic lupus erythematosus.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.